| Tap a line for its trend | Currentlast close | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 2,437 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 95.7 | 95.7 | 25.2 | 32.9 | 27.4 | ||
| 81.8 | 81.8 | 96.4 | 51.3 | 43.8 | ||
| 2,424 | — | — | — | — | ||
| 471 | 471 | 397 | 319 | 268 | ||
| — | +18.6% | +24.4% | +19.2% | — | ||
| 145 | 145 | 119 | 91.1 | 74.7 | ||
| 30.9% | 30.9% | 29.8% | 28.5% | 27.9% | ||
| 99.7 | 99.7 | 79.1 | 64.5 | 54.5 | ||
| 70.1 | 70.1 | 54.7 | 46.4 | 36.9 | ||
| 14.9% | 14.9% | 13.8% | 14.5% | 13.8% | ||
| ₹147.02 | ₹147.02 | ₹114.62 | ₹97.23 | ₹77.43 | ||
| — | +28.3% | +17.9% | +25.6% | — | ||
| — | — | 94.5 | 89.8 | 69.6 | ||
| — | — | 94.5 | 89.8 | 69.6 | ||
From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 2,437.4 | |
| - Cash, Equiv & ST Investments | 27.4 | 32.9 | 25.2 | 95.7 | 95.7 | |
| + Total Debt | 43.8 | 51.3 | 96.4 | 81.8 | 81.8 | |
| Enterprise Value | — | — | — | — | 2,423.6 | |
| Revenue | 267.9 | 319.3 | 397.2 | 470.9 | 470.9 | |
| Growth %, YoY | — | +19.2 | +24.4 | +18.6 | — | |
| EBITDA | 74.7 | 91.1 | 118.5 | 145.3 | 145.3 | |
| Margin % | 27.88 | 28.52 | 29.84 | 30.86 | 30.86 | |
| EBIT | 54.5 | 64.5 | 79.1 | 99.7 | 99.7 | |
| Net Income | 36.9 | 46.4 | 54.7 | 70.1 | 70.1 | |
| Margin % | 13.78 | 14.52 | 13.76 | 14.89 | 14.89 | |
| EPS, Adj (current shares) | 77.43 | 97.23 | 114.62 | 147.02 | 147.02 | |
| Growth %, YoY | — | +25.6 | +17.9 | +28.3 | — | |
| Cash from Operations | 69.6 | 89.8 | 94.5 | — | — | |
| Free Cash Flow | 69.6 | 89.8 | 94.5 | — | — | |
Figures from the company's filings with NSE
In FY26 its consolidated net profit was ₹70.1 crore on revenue of ₹471 crore. Its debt-to-equity ratio was 0.24 on 31 March 2026.
No. Dr Agarwals Eye Hospital had borrowings of ₹81.8 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.24. Its cash and current investments were ₹95.8 crore, so it held net cash of ₹14 crore.
Dr Agarwals Eye Hospital's debt-to-equity ratio was 0.24 on 31 March 2026: borrowings of ₹81.8 crore against total equity of ₹346 crore.
Dr Agarwals Eye Hospital's net worth — shareholders' equity in its consolidated balance sheet — was ₹346 crore on 31 March 2026.
In FY26, Dr Agarwals Eye Hospital's return on equity (ROE) was 25.2% and its return on capital employed (ROCE) was 16.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 29.8% and ROCE 16.8%.
In FY26 (April 2025–March 2026), Dr Agarwals Eye Hospital's consolidated net profit was ₹70.1 crore, up 28.3% from ₹54.7 crore in FY25, on revenue from operations of ₹471 crore (up 18.6%). Over three years, from FY23, net profit was up 89.9%.
In FY26, Dr Agarwals Eye Hospital earned net profit of ₹70.1 crore on revenue of ₹471 crore, against ₹8 lakh on ₹53.7 crore for Lotus Eye Hospital and Institute. Dr Agarwals Eye Hospital's operating margin was 21.2% (Lotus Eye Hospital and Institute −0.7%) and its return on equity 25.2% (Lotus Eye Hospital and Institute 0.1%).
Dr Agarwals Eye Hospital's book value per share was ₹726.29 on 31 March 2026: shareholders' equity of ₹346 crore divided by the 47.68 lakh shares in issue.
Dr Agarwals Eye Hospital's basic earnings per share (EPS) were ₹147.02 in FY26, against ₹116.28 in FY25.
In 2026, Dr Agarwals Eye Hospital has declared one dividend: ₹4 with record date 2 September 2026.
On FY26 consolidated figures, against Lotus Eye Hospital and Institute: Dr Agarwals Eye Hospital's operating margin of 21.2% is the higher of the two (Lotus Eye Hospital and Institute −0.7%; peer average −0.7%); its return on equity of 25.2% is the higher of the two (Lotus Eye Hospital and Institute 0.1%; peer average 0.1%); its revenue growth over three years of 20.7% a year is the higher of the two (Lotus Eye Hospital and Institute 4.5% a year; peer average 4.5% a year).
From Dr Agarwals Eye Hospital's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.